Developing An In Vivo CAR-T With Interius BioTherapeutics' Sianny Christanti and Babu Medi, Ph.D.

On this episode of Better Biopharma, Interius BioTherapeutics’ Sianny Christanti and Babu Medi, Ph.D., explain how the company is re-engineering a lentiviral vector to enable INT2104, its off-the-shelf, in vivo CAR T-cell therapy. They discuss the vector's design and its manufacturability, as well as the analytical and regulatory challenges of bringing this first-in-human therapy to the clinic.

Follow Tyler Menichiello on LinkedIn: https://www.linkedin.com/in/tmenichiello/

Keep up with everything biomanufacturing at Bioprocess Online: https://www.bioprocessonline.com/

Subscribe to our newsletters: https://www.bioprocessonline.com/user/edit/subscriptions